We are live on ! Find out more
RSCM

Rock Springs Capital Management Portfolio holdings

AUM $2.05B
1-Year Est. Return 161.37%
This Fund
S&P 500
This Quarter Est. Return
-0.68%
1 Year Est. Return
+161.37%
3 Year Est. Return
+342.48%
5 Year Est. Return
+531.16%
10 Year Est. Return
+6,258.71%
AUM
$4.76B
AUM Growth
-$304M
Cap. Flow
+$33.1M
Cap. Flow %
0.7%
Top 10 Hldgs %
26.26%
Holding
167
New
11
Increased
69
Reduced
16
Closed
14

Top Buys

Rank Stock Value
1
BAX icon
Baxter International
BAX
+$35.6M
2
WRBY icon
Warby Parker
WRBY
+$35M
3
RARE icon
Ultragenyx Pharmaceutical
RARE
+$30.4M
4
IMRX icon
Immuneering
IMRX
+$29.3M
5
ABOS icon
Acumen Pharmaceuticals
ABOS
+$26.3M

Top Sells

Rank Stock Value
1
ONC
BeOne Medicines Ltd
ONC
+$68.6M
2
ARDX icon
Ardelyx
ARDX
+$39.8M
3
BIIB icon
Biogen
BIIB
+$39.3M
4
BSX icon
Boston Scientific
BSX
+$34.2M
5
PPD
PPD, Inc. Common Stock
PPD
+$31.1M

Sector Composition

Rank Sector Weight
1 Healthcare 95.73%
2 Consumer Staples 1.58%
3 Miscellaneous 1.47%
4 Industrials 0.82%
5 Financials 0.4%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
AGL icon
1
Agilon Health
AGL
$1.54B
$185M 3.9%
283,000
+3,039
+1% +$2.6M
HUM icon
2
Humana
HUM
$47.5B
$133M 2.8%
342,000
+39,500
+13% +$16.8M
ALGN icon
3
Align Technology
ALGN
$10.5B
$133M 2.8%
200,000
+12,250
+7% +$8.32M
PODD icon
4
Insulet
PODD
$9.68B
$124M 2.62%
437,566
+28,816
+7% +$8.22M
ISRG icon
5
Intuitive Surgical
ISRG
$133B
$119M 2.51%
360,000
– –
AGIO icon
6
Agios Pharmaceuticals
AGIO
$1.98B
$118M 2.48%
2,556,179
-18,129
-0.7% -$876K
ZLAB icon
7
Zai Lab
ZLAB
$2.8B
$114M 2.39%
1,077,750
+63,750
+6% +$9.15M
IDXX icon
8
Idexx Laboratories
IDXX
$40.2B
$112M 2.35%
180,000
– –
HCA icon
9
HCA Healthcare
HCA
$91.6B
$109M 2.3%
450,000
– –
NBIX icon
10
Neurocrine Biosciences
NBIX
$15.3B
$101M 2.12%
1,051,500
+36,500
+4% +$3.45M
ARGX icon
11
argenx
ARGX
$61.1B
$95.1M 2%
315,000
– –
NVAX icon
12
Novavax
NVAX
$1.55B
$94.3M 1.98%
455,000
– –
UNH icon
13
UnitedHealth
UNH
$339B
$93.8M 1.97%
240,000
– –
IMCR icon
14
Immunocore
IMCR
$1.63B
$90.6M 1.91%
2,445,155
+50,370
+2% +$1.7M
BPMC
15
DELISTED
Blueprint Medicines
BPMC
$87.4M 1.84%
849,659
+40,799
+5% +$3.8M
HZNP
16
DELISTED
Horizon Therapeutics Public Limited Company Ordinary Shares
HZNP
$76.9M 1.62%
702,000
+77,000
+12% +$7.99M
FRPT icon
17
Freshpet
FRPT
$2.98B
$75.2M 1.58%
527,000
+20,500
+4% +$2.93M
NVTA
18
DELISTED
Invitae Corporation
NVTA
$74.1M 1.56%
2,605,829
+303,797
+13% +$8.9M
NVRO
19
DELISTED
NEVRO CORP.
NVRO
$74M 1.56%
635,700
+104,700
+20% +$13.7M
RARE icon
20
Ultragenyx Pharmaceutical
RARE
$1.3B
$72.3M 1.52%
801,109
+336,109
+72% +$30.4M
ACRS icon
21
Aclaris Therapeutics
ACRS
$815M
$68.5M 1.44%
3,803,232
+40,920
+1% +$656K
EW icon
22
Edwards Lifesciences
EW
$49.4B
$65.9M 1.39%
582,000
– –
ASND icon
23
Ascendis Pharma A/S
ASND
$15.9B
$63.8M 1.34%
400,000
+166,500
+71% +$22.8M
MRTX
24
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$62.5M 1.32%
353,514
+34,429
+11% +$5.54M
PHR icon
25
Phreesia
PHR
$635M
$59.8M 1.26%
970,000
+10,000
+1% +$667K
1
2 3 4 5

Similar funds

ABI
Abrams Bison Investments Bethesda, Maryland $2.05B AUM 71.03% 1-Year Est. Return
FWTB
First Western Trust Bank Denver, Colorado $2.05B AUM 0.32% 1-Year Est. Return
SIC
Sigma Investment Counselors Northville, Michigan $2.05B AUM 18.42% 1-Year Est. Return
RMC
Ribbit Management Company Palo Alto, California $2.05B AUM 4.29% 1-Year Est. Return
DWT
Dorsey & Whitney Trust Sioux Falls, South Dakota $2.05B AUM 30.99% 1-Year Est. Return
CFA
Capstone Financial Advisors Downers Grove, Illinois $2.05B AUM 19.29% 1-Year Est. Return
ABTD
Arvest Bank Trust Division Dewey, Oklahoma $2.05B AUM 30.62% 1-Year Est. Return
JCM
Jacobi Capital Management Pittston, Pennsylvania $2.04B AUM 26.26% 1-Year Est. Return

Rock Springs Capital Management's Q3 2021 Portfolio in Review

As of Q3 2021, Rock Springs Capital Management held 167 positions worth $4.76B, down 6% from $5.06B the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Rock Springs Capital Management's Q3 2021 filing shows 11 new, 69 increased, 16 reduced and 14 closed positions. Its largest new stake was Baxter International: 450,000 shares worth $36.2M. The largest sale was BeOne Medicines Ltd, an estimated $68.6M.

By sector, the portfolio is most concentrated in Healthcare at 96% of assets, down from 96% a quarter earlier, followed by Consumer Staples and Miscellaneous.

  • Rock Springs Capital Management's largest Q3 2021 buy was Baxter International: 450,000 shares worth $36.2M.
  • Rock Springs Capital Management added most to Ultragenyx Pharmaceutical in Q3 2021, an estimated $30.4M increase.
  • Rock Springs Capital Management's biggest Q3 2021 reduction was Prothena Corp, cutting an estimated $14.9M.
  • Rock Springs Capital Management fully exited BeOne Medicines Ltd in Q3 2021, selling an estimated $68.6M.
  • Rock Springs Capital Management's ten largest holdings make up 26% of its $4.76B portfolio in Q3 2021.
  • Rock Springs Capital Management opened 11 new positions and closed 14 in Q3 2021.
  • Rock Springs Capital Management's portfolio value fell 6% quarter-over-quarter to $4.76B.

Based on Rock Springs Capital Management's 13F filing for Q3 2021, filed 15 Nov 2021.